These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 20213465)

  • 1. Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.
    Waring JF; Ciurlionis R; Marsh K; Klein LL; Degoey DA; Randolph JT; Spear B; Kempf DJ
    Arch Toxicol; 2010 Apr; 84(4):263-70. PubMed ID: 20213465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia.
    Lum PY; He YD; Slatter JG; Waring JF; Zelinsky N; Cavet G; Dai X; Fong O; Gum R; Jin L; Adamson GE; Roberts CJ; Olsen DB; Hazuda DJ; Ulrich RG
    Genomics; 2007 Oct; 90(4):464-73. PubMed ID: 17719200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene array screening for identification of drugs with low levels of adverse side effects.
    Bolt HM; Marchan R; Hengstler JG
    Arch Toxicol; 2010 Apr; 84(4):253-4. PubMed ID: 20229237
    [No Abstract]   [Full Text] [Related]  

  • 4. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors.
    Parker RA; Flint OP; Mulvey R; Elosua C; Wang F; Fenderson W; Wang S; Yang WP; Noor MA
    Mol Pharmacol; 2005 Jun; 67(6):1909-19. PubMed ID: 15755908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.
    Liang JS; Distler O; Cooper DA; Jamil H; Deckelbaum RJ; Ginsberg HN; Sturley SL
    Nat Med; 2001 Dec; 7(12):1327-31. PubMed ID: 11726973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
    Pineda JA; Santos J; Rivero A; Abdel-Kader L; Palacios R; Camacho A; Lozano F; Macías J;
    J Antimicrob Chemother; 2008 Apr; 61(4):925-32. PubMed ID: 18276600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.
    Prot M; Heripret L; Cardot-Leccia N; Perrin C; Aouadi M; Lavrut T; Garraffo R; Dellamonica P; Durant J; Le Marchand-Brustel Y; Binétruy B
    Antimicrob Agents Chemother; 2006 Dec; 50(12):3998-4004. PubMed ID: 17000748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
    Naeger LK; Struble KA
    AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism.
    Kim RJ; Wilson CG; Wabitsch M; Lazar MA; Steppan CM
    Obesity (Silver Spring); 2006 Jun; 14(6):994-1002. PubMed ID: 16861604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
    Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
    J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atazanavir: new option for treatment of HIV infection.
    Havlir DV; O'Marro SD
    Clin Infect Dis; 2004 Jun; 38(11):1599-604. PubMed ID: 15156449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations.
    Cohen CJ
    AIDS Read; 2005 Oct; 15(10):528-32, 537-8. PubMed ID: 16265768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M
    J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transcriptomic changes associated with ritonavir-induced hyperlipidemia in sensitive and resistant strains of rats.
    Yang Y; Dahly-Vernon AJ; Blomme EA; Lai-Zhang J; Kempf DJ; Marsh KC; Harrington YA; Nye SH; Evans DL; Roman RJ; Jacob HJ; Waring JF
    Vet J; 2010 Jul; 185(1):75-82. PubMed ID: 20547082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.